Cannabidiol for the treatment of refractory epilepsy in children: a critical review of the literature

Moreira, Gabriela Araujo; Neto, Roddie Moraes; Ribeiro, Ricardo Gullit; Crippa, Ana Chrystina de Souza

doi:10.1590/1984-0462/2023/41/2021197

Cited by 2 publications

(1 citation statement)

References 29 publications

(63 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CBD has been safely used in the treatment of seizures resistant to other ASMs in the pediatric population. 149 CBD has shown mixed results after HI, with some short-term evidence of benefit after immediate IV infusion after HI in piglets during normothermia or TH. 150,151 However, other studies found no evidence of neuroprotection, and hypotension developed during higher-dose therapy.…”

Section: Melatoninmentioning

confidence: 99%

Neuroprotective therapies in the NICU in term infants: present and future

Molloy

El‐Dib²,

Juul³

et al. 2022

Pediatr Res

View full text Add to dashboard Cite

Outcomes of neonatal encephalopathy (NE) have improved since the widespread implementation of therapeutic hypothermia (TH) in high-resource settings. While TH for NE in term and near-term infants has proven beneficial, 30–50% of infants with moderate-to-severe NE treated with TH still suffer death or significant impairments. There is therefore a critical need to find additional pharmacological and non-pharmacological interventions that improve the outcomes for these children. There are many potential candidates; however, it is unclear whether these interventions have additional benefits when used with TH. Although primary and delayed (secondary) brain injury starting in the latent phase after HI are major contributors to neurodisability, the very late evolving effects of tertiary brain injury likely require different interventions targeting neurorestoration. Clinical trials of seizure management and neuroprotection bundles are needed, in addition to current trials combining erythropoietin, stem cells, and melatonin with TH. Impact The widespread use of therapeutic hypothermia (TH) in the treatment of neonatal encephalopathy (NE) has reduced the associated morbidity and mortality. However, 30–50% of infants with moderate-to-severe NE treated with TH still suffer death or significant impairments. This review details the pathophysiology of NE along with the evidence for the use of TH and other beneficial neuroprotective strategies used in term infants. We also discuss treatment strategies undergoing evaluation at present as potential adjuvant treatments to TH in NE.

show abstract

Section: Melatoninmentioning

confidence: 99%

Neuroprotective therapies in the NICU in term infants: present and future

Molloy

El‐Dib²,

Juul³

et al. 2022

Pediatr Res

View full text Add to dashboard Cite

show abstract

Stakeholder Perceptions of Complementary and Integrative Medicines from People Living with Rare Diseases in Northern Ireland: A Mixed Methods Study

Crowe,

Kerr,

McAneney

et al. 2023

Complement Med Res

View full text Add to dashboard Cite

Introduction: Only five percent of rare diseases have an orthodox modern medicine treatment available, therefore patients often utilise complementary and alternative medicines (CAMs) to help manage their condition. Several CAMs are supported by scientific evidence as effective for aiding management of rare diseases, however the methodological rigour of published literature may be sub-optimal and it can be difficult to show that an outcome is a direct result of the CAM intervention. Patients and healthcare professionals must weigh up the safety, efficacy, practical logistics, and financial implications of utilising CAMs for rare diseases. This study aimed to elucidate perspectives of stakeholders, (individuals with rare diseases, carers, family members, CAMs practitioners and healthcare professionals) on the usage of CAMs for rare diseases across Northern Ireland. Methods: An online survey was open January – February 2019 (n = 29 responses). Themes identified from the survey were then discussed with stakeholders in a semi-structured discussion workshop in March, 2019. Results: Patients with rare diseases reported CAMs as effective in the management of their condition, in particular acupuncture, dietary supplements, herbal medicines, homeopathy, hydrotherapy / swimming, kinesiology, mindfulness, pilates, reflexology, tai chi, and yoga. In this study, seven survey respondents experienced a negative side effect from CAMs. Workshop participants raised the lack of information available about CAMs and rare disease. Both the survey and workshop identified inequality of access with participants reporting CAMs to be expensive and expressing a desire for more therapies to be available within the United Kingdom (UK) National Healthcare Service (NHS). Conclusions: Many patients with rare diseases report that CAMs are helpful in the management of their condition. More information, high quality research, and education about CAMs is required for patients and healthcare professionals to help make informed decisions about the usage of CAMs for rare diseases. Improved communication, information, and health and social care in general would help individuals be more confident and knowledgeable about therapeutic options in relation to their rare disease(s).

show abstract

Cannabidiol for the treatment of refractory epilepsy in children: a critical review of the literature

Cited by 2 publications

References 29 publications

Neuroprotective therapies in the NICU in term infants: present and future

Neuroprotective therapies in the NICU in term infants: present and future

Stakeholder Perceptions of Complementary and Integrative Medicines from People Living with Rare Diseases in Northern Ireland: A Mixed Methods Study

Contact Info

Product

Resources

About